Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica
Artículo académico
Cervical cancer affects more than 500,000 women per year worldwide (1). Persistent infection with carcinogenic HPV is the necessary cause of cervical cancer (2), and also causes a subset of cancers of the anus, vulva, vagina, penis, and oropharynx (2), comprising approximately 70,000 additional cases of HPV-associated cancers per year (3). HPV 16 and 18 are responsible for 70% of cervical cancers (4) and for most cases of HPV-driven cancers at the other anatomical sites (5;6). HPV prophylactic vaccines have the potential to dramatically reduce the burden of HPV-associated disease if incorporated into cervical cancer prevention programs, especially in developing countries.